Blood
Articles in this Issue
High morbidity and early readmissions in thrombotic thrombocytopenic purpura requiring intensive care: Insights from a national database
Abstract Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening thrombotic microangiopat...
Evolving burden of acute kidney injury in non-Hodgkin's lymphoma hospitalizations: A seven-year nationwide study
Abstract Background: Acute Kidney Injury (AKI) is a significant complication among hospitalized patients with Non-Hodgki...
Coronary artery calcification and its effect on cardiac events in patients undergoing allogeneic stem cell transplantation using nonmyeloablative conditioning
Abstract Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) using non-myeloablative (NMA) conditioning has improve...
Machine Learning–Guided identification of survival-associated genetic variants in sickle cell disease
Abstract Sickle cell disease is an inherited red cell disorder that arises from a single nucleotide mutation in the beta hemoglobin gene, ye...
Risk of secondary chronic myeloid leukemia in cancer survivors: A nationwide population-based study in Taiwan
Abstract Background. Secondary chronic myeloid leukemia (CML) is a rare but serious late complication in cancer survivors. Despite its clini...
Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study
Abstract Treatment of relapsed/refractory primary mediastinal B-cell lymphoma (R/R PMBCL) patients has been revolutionized by the advent of...
Synkir-310 split-signaling based KIR-CAR T cell therapy achieves faster and deeper anti-B cell tumor efficacy with reduced cytokine levels
Abstract Currently, five CD19-targeting chimeric antigen receptor (CAR) T cells are FDA-approved for treatment of B cell malignancies. These...
Auto-HSCT combined with blinatumomab as an allo-HSCT-sparing strategy in newly diagnosed B-ALL: Phase II trial results
Abstract Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment for AYA and adult with Ph-...
Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy
Abstract Introduction: Tumor burden (TB) is a well-established prognostic factor in relapsed/refractory large B cell lymphoma (R/R LBCL) tre...
Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDPM) in Relapsed/Refractory diffuse large B-cell lymphoma: A multicenter, single-arm study
Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive subtype of non-Hodgkin lymphoma (NHL), with approximately...
Targeting TP53 promotes anti-leukemia immunity and enhances CD70 CAR-T efficacy in AML by transcriptionally upregulating CD70
Abstract Cancer Immunotherapy, particularly chimeric antigen receptor (CAR) therapy, has achieved unprecedented success in blood cancers of...
Daratumumab-pomalidomide-dexamethasone (DPd) in newly diagnosed AL amyloidosis: High rates of hematologic and organ responses with manageable safety
Abstract Introduction Preliminary studies have demonstrated that the combination of daratumumab (Dara), pomalidomide (Po...
Adeno-associated viral integration profiles in human liver biopsies following Hemophilia A gene therapy
Abstract Introduction: Adeno-associated viral (AAV) gene therapy has received approvals for the treatment of severe hemophilia A. Preclinica...
Polatuzumab vedotin plus R-CHP demonstrates high efficacy with manageable toxicity in treatment-Naïve dual-expressor DLBCL (DEL): Real-world analysis with focus on elderly high-risk patients
Abstract Background: Dual-expressor DLBCL (DEL), characterized by MYC/BCL2 co-expression (20-30% of cases), demonstrates inferior outcomes wi...
A massive overdose of 6,600mg enoxaparin and its treatment with protamine
Abstract We report a case of an intentional massive overdose of 6,600mg (660,000 IU) enoxaparin, which is the highest enoxaparin administrat...
Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)
Abstract Background: CTCs and MRD are rare tumor cell populations that respectively disseminate MM and drive relapse after treatment. If its...
Determinants of survival in primary cutaneous CD4+ small-to-medium-sized pleomorphic t-cell lymphoproliferative disorder (PC4SMPTCL): Analysis of a real-world pooled database
Abstract Background: PC4SMPTCL is a rare and distinct entity within the spectrum of cutaneous T-cell lymphomas, recognized for its predomina...
Survival outcomes in therapy-related acute lymphoblastic leukemia: A population-based analysis from SEER (2000–2022)
Abstract Background Therapy-related acute lymphoblastic leukemia (t-ALL) is a rare and poorly characterized entity typically arising after c...
Clinical outcome of patients with TP53 AML treated with non-intensive vidaza-venetoclax chemotherapy : Venaura retrospective regional multicenter study.
Abstract Acute myeloid leukemias (AML) with TP53 mutations represent a distinct biological entity, recently recognized in the WHO 2022 and I...
Real-world use of prophylaxis in people with non-severe hemophilia in the United States: Insights from the athn transcends Study - hemophilia natural history arm
Abstract Introduction: People with mild to moderate hemophilia are frequently underrepresented in clinical trials and registries, leading to...
Efficacy and safety of Bruton's tyrosine kinase inhibitors in adults with immune thrombocytopenic purpura: A systematic review and meta-analysis
Abstract Introduction: Immune thrombocytopenic purpura (ITP) is an autoimmune hematologic disorder characterised by autoantibody-mediated pl...
Budget impact analysis of rituximab biosimilar in patients with haematological cancers in Qatar
Abstract Objective: Rituximab is widely used in the management of several haematological malignancies. Biosimilars of rituximab, such as Rex...
Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study
Abstract Introduction: Cilta-cel is approved in the US and the EU for the treatment of patients (pts) with lenalidomide-refractory multiple...
Tissue factor and extracellular vesicles from PASC patients exert procoagulant effects and mediates venous thrombosis in a murine model
Abstract Post-acute sequelae of SARS-CoV-2 infection (PASC) is recognized as a syndrome marked by persistent thromboinflammation, even in in...
Salvage allogeneic hematopoietic stem cell transplantation conditioning regimens for relapsed/refractory acute leukemia: Efficacy of radiotherapy combined with CLAG vs FLAG
Abstract Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative option for relapsed/refractory acute leukemia (...